AccueilEVGN • NASDAQ
add
Evogene
Dernière clôture
0,94 $
Variation sur la journée
0,93 $ - 1,10 $
Plage sur l'année
0,93 $ - 2,42 $
Capitalisation boursière
9,58 M USD
Volume moyen
55,63 k
Ratio cours/bénéfices
-
Rendement (dividendes)
-
Place boursière principale
NASDAQ
Données financières
Compte de résultat
Chiffre d'affaires
Résultat net
| (USD) | sept. 2025info | Variation Y/Y |
|---|---|---|
Chiffre d'affaires | 312,00 k | -82,63 % |
Charges d'exploitation | 2,88 M | -64,76 % |
Résultat net | 3,87 M | 150,77 % |
Marge bénéficiaire nette | 1,24 k | 392,27 % |
Bénéfice par action | -0,46 | 64,51 % |
EBITDA | -2,44 M | 64,22 % |
Taux d'imposition effectif | -0,04 % | — |
Bilan
Total des actifs
Total du passif
| (USD) | sept. 2025info | Variation Y/Y |
|---|---|---|
Trésorerie/Invest. court terme | 15,96 M | -20,02 % |
Total des actifs | 26,09 M | -34,97 % |
Total du passif | 8,83 M | -68,31 % |
Total des capitaux propres | 17,25 M | — |
Actions en circulation | 8,72 M | — |
Ratio cours/valeur comptable | 7,23 | — |
Rentabilité des actifs | -22,70 % | — |
Retour sur capitaux | -39,13 % | — |
Flux de trésorerie
Variation nette en trésorerie
| (USD) | sept. 2025info | Variation Y/Y |
|---|---|---|
Résultat net | 3,87 M | 150,77 % |
Trésorerie (opérations) | -3,33 M | 32,37 % |
Trésorerie (invest.) | 10,91 M | 441,12 % |
Trésorerie (financement) | -10,34 M | -318,34 % |
Variation nette en trésorerie | -2,70 M | -247,46 % |
Flux de trésorerie dispo. | -385,62 k | -131,18 % |
À propos
Evogene is a computational chemistry company based in Israel, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries. At the core of its technology is ChemPass AI, a proprietary generative AI engine that enables the design of novel, highly potent small molecules optimized across multiple critical parameters. This powerful platform significantly improves success rates while reducing development time and costs. Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products driven by the integration of scientific innovation with real-world industry needs.
In 2024, the company began collaborating with Google Cloud to develop an AI-powered generative model aimed at discovering small molecules for drug development and sustainable agriculture. Wikipedia
CEO
Date de fondation
1999
Site Web
Employés
117
